Abstract：Objective：To observe the efficacy of Yiqi Huoxue Huatan Prescription in the treatment of stable-stage chronic obstructive pulmonary disease （COPD） of qi deficiency， blood stasis， and phlegm obstruction type． Methods：A total of 92 patients with stable-stage COPD of qi deficiency，blood stasis，and phlegm obstruction type， admitted to The First Affiliated Hospital of Henan University from January 2023 to January 2025，were selected．They were randomly divided into the western medicine group and the decoction group using the lottery method，with 46 cases in each group．The western medicine group received conventional treatment，while the decoction group received Yiqi Huoxue Huatan Prescription in addition to the conventional treatment． After 12 weeks of treatment， the clinical efficacy and incidence of adverse reactions were compared between the two groups． Changes in traditional Chinese medicine syndrome scores，pulmonary functional status and symptom severity [6-minute walk test （6MWT），modified Medical Research Council Dyspnea Scale （mMRC），COPD Assessment Test （CAT） score]，lung function [forced vital capacity（ FVC），forced expiratory volume in one second（ FEV1），FEV1/FVC ratio]，and levels of inflammatory factors [interleukin-6 （IL-6），tumor necrosis factor-α （TNF-α）] before and after treatment were also compared．Results： After treatment，the total effective rate was 91.30% （42/46） in the decoction group and 73.91% （34/46） in the western medicine group， with a statistically significant difference between the two groups （P＜0.05）. After 12 weeks of treatment， the traditional Chinese medicine syndrome scores in both groups decreased compared with those before treatment（ P＜0.05），and the score in the decoction group was lower than that in the western medicine group（ P＜0.05）. After treatment，the 6MWT distance increased in both groups compared with that before treatment （P＜0.05），and the distance in the decoction group was longer than that in the western medicine group （P＜0.05）．The CAT and mMRC scores decreased in both groups compared with those before treatment （P＜0.05）， and both scores in the decoction group were lower than those in the western medicine group （P＜0.05）． After treatment， the levels of FEV1， FVC， and FEV1/FVC increased in both groups compared with those before treatment （P＜0.05），and the levels of all three indicators in the decoction group were higher than those in the western medicine group （P＜0.05）． After treatment， the levels of TNF-α and IL-6 decreased in both groups compared with those before treatment （P＜0.05），and the levels of both indicators in the decoction group were lower than those in the western medicine group （P＜0.05）．The incidence of adverse reactions was 8.70% （4/46） in the decoction group and 4.35% （2/46） in the western medicine group， showing no statistically significant difference between the two groups （P＞0.05）．Conclusion：Yiqi Huoxue Huatan Prescription can regulate lung function and inflammatory factor levels in patients with stable-stage COPD of qi deficiency， blood stasis， and phlegm obstruction type． It can improve traditional Chinese medicine syndromes， exercise tolerance，symptom severity，and enhance clinical efficacy.